Keuangan Revolution Medicines, Inc. (RVMD)
NASDAQ · Healthcare · Biotechnology · Karyawan: 883 · CEO: Mark A. Goldsmith
- Harga
- $191,31 +0,55%
- Kapitalisasi pasar
- $41 M
- Nilai perusahaan
- $40,8 M
- Laporan terakhir
- Q2 '26 diajukan 2026-08-05
- Laporan berikutnya
- 2026-11-04 Estimasi EPS: -$2,35
Pendapatan (TTM)$0– vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)–– vs tahun laluLaba operasional: -$1,63 M
Laba bersih (TTM)-$1,77 M-117,8% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)-$1,23 M-75,9% vs tahun laluCapex: $9,1 jt
EPS dilusian (TTM)-$8,86-96,5% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$3,3 M+64,4% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $41 M EV $40,8 M
- Pendapatan
- $0 12 bulan terakhir
- Pertumbuhan pendapatan
- – Konsensus FY2026
- Margin laba
- – Laba bersih / pendapatan, TTM
- P/E
- -21,6× Forward -20,2× (FY2026)
- P/S
- 0,0× Harga / penjualan, TTM
- EV / EBITDA
- -24,1× TTM
- Arus kas bebas
- -$1,23 M 12 bulan terakhir
- Laba bersih
- -$1,77 M 12 bulan terakhir
- Estimasi pendapatan
- $208 jt Konsensus FY2026
- Laba
- 2026-11-04 Estimasi pendapatan: $25,6 jt
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-05): pendapatan n/a, EPS meleset 50,0%Pendapatan – vs $1,77 jt yang diharapkan (–); EPS -$3,06 vs -$2,04 (-50,0%).
- Jumlah saham dilusian naik dalam setahun: 12,1%Saham dilusian pada Q2 '26: 211 jt, setahun sebelumnya: 188 jt.
- Kas neto: $3,3 MKas + investasi jangka pendek: $3,94 M, utang termasuk sewa: $642 jt; tahun lalu kas neto: $2 M.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $0 | $0 | – |
| Laba operasional | -$505 jt | -$265 jt | -90,8% |
| Laba bersih | -$644 jt | -$248 jt | -160,1% |
| EPS dilusian | -$3,06 | -$1,31 | -133,6% |
| Arus kas operasional | -$387 jt | -$222 jt | -74,7% |
| Capex | $2,29 jt | $7,45 jt | -69,3% |
| Arus kas bebas | -$390 jt | -$229 jt | -70,0% |
| R&D | $395 jt | $224 jt | +76,2% |
| Kompensasi berbasis saham | $0 | $28,8 jt | -100,0% |
Dilaporkan vs konsensus
2026-08-05| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| EPS (basis konsensus) | -$3,06 | -$2,04 | -50,0% |
Dari laporan 2026-08-05 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q1 '23 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Collaboration Revenue Member | $7,01 jt | – | 100,0% | $34,8 jt | – |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- -$1,22 M
- Capex
- -$9,1 jt
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- $0
- Utang neto diterbitkan
- $976 jt
- Kompensasi berbasis saham
- $152 jt
- Arus kas bebas
- -$1,23 M
- Dikembalikan ke pemegang saham / FCF
- 0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -21,6× | – | – |
| EV / EBITDA | -24,1× | – | – |
| EV / Penjualan | 0,0× | 113,4× 3 dari 5 tahun | 51,5× – 227,7× |
| Harga / FCF | -33,3× | – | – |
| Harga / Nilai buku | 15,5× | 4,0× | 1,8× – 9,3× |
| Imbal hasil FCF | -3,0% | -9,1% | -12,2% – -6,0% |
| Imbal hasil modal yang diinvestasikan | -40,8% | -34,4% | -56,8% – -25,1% |
| Imbal hasil ekuitas | -96,4% | -37,4% | -69,3% – -23,9% |
Analis
Target konsensus $253,47 (+32,5%)
rentang $179,00 – $320,00 · peringkat Buy
Beli kuat1
Beli22
Tahan2
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $208 jt | – | -$9,49 | -59,5% | -20,2× | 19 |
| FY2027 | $1,23 M | +492,6% | -$5,79 | +39,0% | -33,0× | 19 |
| FY2028 | $2,61 M | +111,9% | -$2,41 | +58,5% | -79,5× | 18 |
| FY2029 | $5 M | +91,5% | $5,82 | +342,0% | 32,9× | 9 |
| FY2030 | $8,16 M | +63,2% | $15,21 | +161,2% | 12,6× | 8 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 205 angka yang ditandai Revolution Medicines, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $88,4 jt | $56,8 jt | +55,8% | $64,6 jt | $54,4 jt | +18,7% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $4,33 jt | $7,74 jt | -44,0% | $27,8 jt | $44,6 jt | -37,5% |
| Accrued Employee Benefits, Current | $64,7 jt | $21,7 jt | +197,7% | $58,2 jt | $30,8 jt | +89,1% |
| Accrued Liabilities, Current | $5 jt2026-03-31 | – | – | $5 jt | – | – |
| Accrued Professional Fees, Current | $8,94 jt | $2,91 jt | +206,9% | $6,14 jt | $1,62 jt | +278,1% |
| Accrued Royalties | $549 jt | $245 jt | +123,8% | $268 jt | $0 | – |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $32,8 jt | $25 jt | +31,2% | $28,5 jt | $21,8 jt | +30,7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$5,95 jt | $1,3 jt | -557,0% | $3,24 jt | $1,32 jt | +145,0% |
| Additional Paid in Capital, Common Stock | $6,58 M | $4,06 M | +61,9% | $4,5 M | $4 M | +12,4% |
| Adjustments to Additional Paid in Capital, Warrant Issued | – | – | – | $95,4 jt2024-12-31 | – | – |
| Amortization of Debt Issuance Costs | $419 rb | – | – | $541 rb | – | – |
| Amortization of Intangible Assets | $0 | $300 rb | -100,0% | $870 rb | $1,07 jt | -18,6% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,16 jt | 704 rb | +65,0% | 24,5 jt | 19,4 jt | +26,2% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $67 jt | $28,8 jt | +132,4% | $118 jt | $79,2 jt | +49,5% |
| Asset Impairment Charges | $02025-09-30 | $0 | – | – | – | – |
| Assets | $4,32 M | $2,43 M | +77,9% | $2,35 M | $2,56 M | -8,0% |
| Assets, Current | $4,03 M | $2,18 M | +85,1% | $2,08 M | $2,33 M | -10,9% |
| Business Combination, Consideration Transferred | – | – | – | $1,1 M | $1,1 M | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents | $861 jt2025-12-31 | $861 jt | 0,0% | $861 jt | $861 jt | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability | $490 rb2025-12-31 | $490 rb | 0,0% | $490 rb | $490 rb | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities | $314 jt2025-12-31 | $314 jt | 0,0% | $314 jt | $314 jt | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets | $12,1 jt2025-12-31 | $12,1 jt | 0,0% | $12,1 jt | $12,1 jt | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable | $6,89 jt2025-12-31 | $6,89 jt | 0,0% | $6,89 jt | $6,89 jt | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $1,15 M2025-12-31 | $1,15 M | 0,0% | $1,15 M | $1,15 M | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets | $2,91 jt2025-12-31 | $2,91 jt | 0,0% | $2,91 jt | $2,91 jt | 0,0% |
| Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net | $55,9 jt2025-12-31 | $55,9 jt | 0,0% | $55,9 jt | $55,9 jt | 0,0% |
| Capital Expenditures Incurred but Not yet Paid | $3 jt | $122 rb | +2.354,9% | $1,88 jt | $1,58 jt | +19,0% |
| Cash and Cash Equivalents, at Carrying Value | $815 jt | $402 jt | +102,6% | $384 jt | $543 jt | -29,3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $820 jt | $406 jt | +101,9% | $389 jt | $547 jt | -28,9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $820 jt | $406 jt | +101,9% | $389 jt | $547 jt | -28,9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $374 jt | $69,1 jt | +441,9% | -$158 jt | -$152 jt | -3,8% |
| Common Stock, Capital Shares Reserved for Future Issuance | 37,7 jt | 32,9 jt | +14,6% | 28,6 jt | 31,7 jt | -9,7% |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 300 jt | 300 jt | 0,0% | 300 jt | 300 jt | 0,0% |
| Common Stock, Shares, Issued | 214 jt | 187 jt | +14,6% | 197 jt | 186 jt | +6,0% |
| Common Stock, Shares, Outstanding | 214 jt | 187 jt | +14,6% | 197 jt | 186 jt | +6,0% |
| Common Stock, Value, Issued | $21 rb | $18 rb | +16,7% | $19 rb | $18 rb | +5,6% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$650 jt | -$248 jt | -161,8% | -$1,13 M | -$599 jt | -88,4% |
| Convertible Notes Payable, Noncurrent | $487 jt | – | – | – | – | – |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Foreign Tax Expense (Benefit) | – | – | – | $0 | -$42 rb | +100,0% |
| Current Income Tax Expense (Benefit) | – | – | – | $0 | -$15 rb | +100,0% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $0 | $27 rb | -100,0% |
| Debt Securities, Available-for-sale | $3,88 M | $2,14 M | +81,8% | $2,02 M | $2,29 M | -11,5% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $151 rb | $1,59 jt | -90,5% | $3,28 jt | $1,87 jt | +75,8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $6 jt | $292 rb | +1.954,8% | $44 rb | $545 rb | -91,9% |
| Debt Securities, Available-for-sale, Amortized Cost | $3,89 M | $2,14 M | +82,1% | $2,02 M | $2,29 M | -11,6% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | -$17 rb | +100,0% |
| Deferred Income Tax Expense (Benefit) | – | – | – | $0 | -$738 rb | +100,0% |
| Deferred Income Tax Liabilities, Net | $2,35 jt | $2,35 jt | 0,0% | $2,35 jt | $2,35 jt | 0,0% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | -$721 rb | +100,0% |
| Deferred Tax Assets, Gross | $982 jt2025-12-31 | $609 jt | +61,3% | $982 jt | $609 jt | +61,3% |
| Deferred Tax Assets, Net of Valuation Allowance | $53,9 jt2025-12-31 | $45,1 jt | +19,5% | $53,9 jt | $45,1 jt | +19,5% |
| Deferred Tax Assets, Operating Loss Carryforwards | $436 jt2025-12-31 | $227 jt | +92,3% | $436 jt | $227 jt | +92,3% |
| Deferred Tax Assets, Other | $1,1 jt2025-12-31 | $1,14 jt | -3,7% | $1,1 jt | $1,14 jt | -3,7% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $132 jt2025-12-31 | $66 jt | +100,2% | $132 jt | $66 jt | +100,2% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $33,5 jt2025-12-31 | $20,2 jt | +65,5% | $33,5 jt | $20,2 jt | +65,5% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | $20,3 jt2025-12-31 | $9,95 jt | +103,9% | $20,3 jt | $9,95 jt | +103,9% |
| Deferred Tax Assets, Valuation Allowance | $929 jt2025-12-31 | $564 jt | +64,7% | $929 jt | $564 jt | +64,7% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-02